Comparator sourcing promotional product list 

Oximio offers a collaborative approach to meet the needs of our clients’ comparator sourcing strategies. Sourcing and benchmarking high-quality, and often hard to find comparators, we provide efficient and effective delivery methods to support our clients’ studies.

Our comparator sourcing service includes:

  • Prices that can potentially be negotiated depending on the order quantity and terms of supply
  • Expedited request processing across multiple countries, with minimal “PO to Dispatch” timelines
  • Full sets of documentation including CoA, CoC, MSDS, are available – where stated for each product
  • Provision of end-to-end logistics support with cross-border shipping, management of labelling requirements and local distribution to sites
MA Origin Name Documents
EU/1/00/145/001 EU HERCEPTIN, Roche, 150mg INF (pow for con), 1 vial COA (Mother Batch) - PEDIGREE
EU/1/13/850/001 EU IMNOVID, BMS, 1 mg 21 capsules COA/COC
EU/1/13/850/002 EU IMNOVID, BMS, 2 mg 21 capsules COA/COC
EU1/13/850/004 EU IMNOVID, BMS, 4 mg 21 capsules COA/COC
UA/18299/01/03 Ukraine POMALIDOMIDE-VISTA, Synthon, 4 mg, 21 (7x3) capsules COA/pedigree
UA/16209/01/01 Ukraine KEYTRUDA, MSD, conc. for infus. sol. 25 mg/ml vial 4 ml, 1 vial All documents inc Equivalency Statement
UA/16818/01/02 Ukraine HUMIRA, Abbvie, sol. for inj. 40 mg/0,4 ml, 2 PFS+2 alcohol pads WITH COA
169 82 36204 00 Israel XTANDI, Astellas Pharma, 40mg, 4x28 tablets POD
151 21 33948 01 Israel KYPROLIS, Amgen, powd. for sol. for inj. 60mg/10ml, 1 vial POD
154 38 34448 00 Israel KEYTRUDA, MSD, conc. for infus. sol. 25 mg/ml vial 4 ml, 1 vial POD
157 14 34685 00 Israel EMPLICITI, Bristol Myers Squibb, 400 mg, 1 vial POD
159 97 35280 00 Israel DURVALUMAB, Astrazeneca, 50 mg/ml vial 1/pk POD
161 64 35470 00 Israel OLAPARIB, Astrazeneca, 150 mg tablets 56/pk POD
რ-032628 Georgia AVASTIN, Roche, conc. for infus. sol. 400 mg/16 ml, 1 vial WITH COA

For quotes, please fill out the form below:

"*" indicates required fields

I would like to receive Oximio’s newsletter by email. I understand I can opt out at any time.

By submitting this form, I acknowledge that I have reviewed and understood the Privacy Policy Statement.